2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125554
    KDdiA-PC 439904-34-4 98%
    KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL).
    KDdiA-PC
  • HY-125626
    8-iso-15-keto Prostaglandin F2α 191919-01-4 98%
    8-iso-15-keto Prostaglandin F2α (8-iso-15-keto PGF2α) is a partial agonist for Thromboxane receptor (TP), which exhibits a vasoconstrictor efficacy with a pD2 of 5.8. 8-iso-15-keto Prostaglandin F2α mediates a weak relaxation of rats aorta rings at high concentration.
    8-iso-15-keto Prostaglandin F2α
  • HY-125705
    Herquline A 71812-08-3 98%
    Herquline A (Herqueline A) is a fungal piperazine alkaloid. Herquline A is a fungal metabolite that inhibits platelet aggregation and replication of the influenza virus.
    Herquline A
  • HY-125807
    IS20 324561-95-7 98%
    IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin (HY-15142A) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research.
    IS20
  • HY-126081
    (8-epi)-BW 245C 65705-83-1 98%
    (8-epi)-BW 245C is the C-8 diastereomer of BW 245C (HY-101987). BW 245 C is a high affinity and selective PGD2 receptor agonist.
    (8-epi)-BW 245C
  • HY-126084
    Carbaprostacyclin methyl ester 69552-55-2 98%
    Carbaprostacyclin methyl ester is a methylated derivative of Carbacyclin (HY-112322).
    Carbaprostacyclin methyl ester
  • HY-126115
    15(S)-Latanoprost 145773-22-4 98%
    15(S)-Latanoprost is an analog of latanoprost in which the hydroxyl at carbon 15 is inverted relative to latanoprost. The IC50 values for the free acid forms of latanoprost and 15(S)-latanoprost were determined to be 3.6 nM and 24 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle. A 3 μg dose of 15(S)-latanoprost caused a 1 mmHg reduction of IOP in normotensive cynomolgus monkeys.
    15(S)-Latanoprost
  • HY-126293
    Apelin agonist 1 2227512-85-6 98%
    Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the APJ (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0.
    Apelin agonist 1
  • HY-126336
    HM12 2376051-91-9 98%
    HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc.
    HM12
  • HY-126401
    Elgodipine 119413-55-7 98%
    Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function.
    Elgodipine
  • HY-126568
    Naftidrofuryl 31329-57-4 98%
    Naftidrofuryl (Nafronyl) is a compound that has the ability to enhance cellular oxidative capacity and antispasmodic activity. Naftidrofuryl is used to inhibit peripheral and cerebrovascular diseases. Naftidrofuryl is claimed to improve blood circulation.
    Naftidrofuryl
  • HY-126704
    Tedisamil 90961-53-8 98%
    Tedisamil (KC-8857) is an antiarrhythmic compound with important biological activities. Tedisamil exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models.
    Tedisamil
  • HY-126826
    Antibiotic K 4 84890-90-4 98%
    Antibiotic K 4 is an inhibitor of angiotensin I converting enzyme (ACE) (Ki: 0.18 μM). Antibiotic K 4 inhibits pressor response to angiotensin I in rats.
    Antibiotic K 4
  • HY-126849
    3-Morpholinosydnonimine 33876-97-0 98%
    3-Morpholinosydnonimine (SIN-1) is a spontaneous ROS/RNS generator and peroxynitrite donor. 3-Morpholinosydnonimine is a vasodilator and platelet aggregation inhibitor. 3-Morpholinosydnonimine induces oxidative stress-induced chondrocyte apoptosis and necrosis. 3-Morpholinosydnonimine inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of 3-Morpholinosydnonimine shows protective effects on Zn2+ treated nerve cells.
    3-Morpholinosydnonimine
  • HY-12689C
    Mitapivat hydrochloride 2559738-69-9 98%
    Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric pyruvate kinase R (PK-R) activator. Mitapivat hydrochloride accelerates the reaction of PK-R catalyzing the conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolytic pathway, increasing the production of adenosine triphosphate (ATP) in red blood cells, and reducing the level of 2,3-diphosphoglycerate (2,3-DPG). Mitapivat hydrochloride is promising for research of pyruvate kinase deficiency and other anemia-related diseases.
    Mitapivat hydrochloride
  • HY-126907
    A32390A 61241-59-6 98%
    A32390A is a dopamine β-hydroxylase inhibitor and copper chelator. A32390A can inhibit the synthesis of norepinephrine, which helps lower blood pressure in DOCA hypertensive rats. A32390A can be used in research on hypertension, bacterial infections, and metabolic disorders.
    A32390A
  • HY-126923
    2,3-Dinor thromboxane B2 63250-09-9 98%
    2,3-Dinor thromboxane B2 (2,3-Dinor-TXB2), a metabolite of urine, serves as an indicator of the production of thromboxane A2 (TxA2) in the body, and can be used as a tool to study the role of thromboxane in various pathophysiological processes in the human body.
    2,3-Dinor thromboxane B2
  • HY-12749B
    (R)-Midodrine hydrochloride 133163-28-7 98%
    (R)-Midodrine hydrochloride is a vasopressor used as an antihypertensive agent for the treatment of symptomatic postural hypotension, exhibiting peripheral alpha(1)-adrenoreceptor agonistic activity that induces venous and arterial vasoconstriction.
    (R)-Midodrine hydrochloride
  • HY-12753S
    Debutyldronedarone-d7 ≥98.0%
    Debutyldronedarone-d7 is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active metabolite of dronedarone (HY-A0016) in humans.Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent.
    Debutyldronedarone-d7
  • HY-12760S
    Indoramin-d5 57165-41-0 98%
    Indoramin-d5 is deuterium labeled Indoramin, which is a piperidine antiadrenergic agent.
    Indoramin-d5
Cat. No. Product Name / Synonyms Application Reactivity